Business
Ten-Year Pivotal Data Demonstrate Long-Term Durability of Edwards Lifesciences’ Resilia Tissue
CHICAGO, May 02, 2026--Edwards Lifesciences (NYSE: EW) today announced 10-year results from the COMMENCE aortic trial, reinforcing the long-term durability and sustained performance of its proprietary RESILIA tissue. The data were presented at the 106th American Association for Thoracic Surgery Annual Meeting.
About this update from Edwards Lifesciences Corporation
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/a9f5cf91676f86f86456620fbe728b6d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/WUANM9Kf57FeI9eZdA8aRg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MA--/https://media.zenfs.com/en/business-wire.com/a9f5cf91676f86f86456620fbe728b6d","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/RlmyKxLztDSog3xQNC6OSA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0/https://media.zenfs.com/en/business-wire.com/a9f5cf91676f86f86456620fbe728b6d","width":1024,"height":512}},"lazy":false},{"type":"text","content":"CHICAGO, May 02, 2026--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced 10-year results from the COMMENCE aortic trial, reinforcing the long-term durability and sustained performance of its proprietary RESILIA tissue. The data were presented at the 106th American Association for Thoracic Surgery Annual Meeting.","length":328,"tagName":"p"},{"type":"text","content":"As evidence increasingly supports treating patients earlier in the valve disease pathway, the need for durable valve solutions continues to grow. The COMMENCE trial provides prospective, 10-year data demonstrating the durability of Edwards’ RESILIA tissue and its role in lifetime management for patients with aortic stenosis. To date, more than 500,000 patients worldwide have been treated with Edwards’ surgical and transcatheter innovations featuring RESILIA tissue.","length":469,"tagName":"p"},{"type":"text","content":"At 10 years, COMMENCE trial data showed that patients treated with Edwards’ surgical valves featuring RESILIA tissue experienced:","length":129,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"97.9% freedom from structural valve deterioration (SVD)","length":55,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"97.8% freedom from reoperation due to SVD","length":41,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"98.6% freedom from non-structural valve dysfunction (other than PVL)","length":68,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Sustained hemodynamic performance, including stable gradients and effective orifice area over time","length":98,"tagName":...